This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wouldn't Touch This Stock With a 10-Foot Pole

This article originally appeared Sept. 9, 2013, on Real Money. To read more content like this, + see inside Jim Cramer's multi-million dollar portfolio for FREE Click Here NOW.

Emeritus (ESC) was the biggest loser on the NYSE Friday, losing 10% for the session. Such declines normally pique my interest, as I like to look for shares that are undeservedly punished. But in the case of Emeritus, I believe the outlook really is bleak.

Based in Seattle, the company operates approximately 500 senior-living facilities. Most of them offer assisted-living arrangements. Some are geared toward skilled nursing care, or toward care for people with Alzheimer's disease or dementia.

The company is headed for its eighth consecutive annual loss, and analysts expect this year's loss -- with estimates at about $2.19 a share -- to be the widest in that eight-year period.

As of June 30, Emeritus had almost $4 billion in long-term debt, and debt was about 19x stockholders' equity. By comparison, that ratio is 1.7x at Kindred Healthcare (KND - Get Report), which competes with Emeritus in senior-living facilities and also owns hospitals and rehabilitation centers.

On this point, I tend to be conservative: Generally, I will not buy a stock with a ratio higher than 1x.

Valuations at Emeritus are forbidding from a value investor's perspective. There is, of course, no price-to-earnings ratio, since there are no earnings. The stock sells for 5x book value (corporate net worth per share), which is about double the ratio for the average stock and more than double my preferred limit of 2x.

The shares do look more reasonable on a price-to-sales multiple, as they fetch only 0.5x sales. This ratio can often point to a turnaround situation, as new management may be able to come in and reshape the clay of sales into the pottery of earnings.

I do not believe, however, that Emeritus is about to turn around. Care for the elderly is inherently expensive, and it's getting more so with longer life spans and newer medical techniques. The relatives of the elderly often lack enough resources to pay for long-term care, and this will become increasingly true as more baby boomers start to need it.

Private long-term care insurance is spotty, and often not up to the task. That leaves Medicare and Medicaid to carry much of the freight. But both programs, and especially Medicaid, are at risk for budget cuts in this fall's Congressional budget negotiation.

A successful company has a product or service that fills a genuine need, and a customer population that can afford to pay for the product. There is a big need for elder care, all right. But it is difficult and expensive to provide it well, and the ability of the customers to pay for the service is in doubt.

At the time of publication, Dorfman had no positions in the stocks mentioned.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,701.15 -129.61 -0.73%
S&P 500 2,059.10 -16.71 -0.81%
NASDAQ 4,768.6640 -36.6270 -0.76%

Our Tweets

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs